Thyroid Cancer (TC): Market View

• In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of thyroid cancer, representing a large portion of global cases.
• Currently, approved targeted therapies have already become a part of the standard care for advanced thyroid cancer (with drugs selected based on the tumor’s genetic profile), and immunotherapies are emerging as experimental options that might benefit certain patients.
• The thyroid cancer pipeline holds 119 molecules, with no assets in the pre-registration stage, and eight assets in Phase III development.
• Over the past decade, 575 clinical trials have been conducted in thyroid cancer. The years with the most studies initiated were 2023 and 2022, with 66 trials, followed by 2021 with 62 trials.
• During the past 22 months, 13 mergers and acquisitions and 18 strategic alliances involving companies developing thyroid cancer assets were completed globally.
• Ipsen/Exelixis, Ono Pharmaceutical, and Novartis dominate the thyroid cancer treatment landscape by marketing novel targeted therapies, and Novartis appears to retain its position with three targeted therapies in its late-stage pipeline.

Report Scope

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Thyroid Cancer Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Thyroid Cancer Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.